National Advertising Division Finds Certain Nemluvio Claims Supported; Recommends Galderma Modify or Discontinue "As Soon as 48 Hours" Claims

In a challenge brought by competitor Sanofi, BBB National Programs’ National Advertising Division found certain Galderma ...
The American Journal of Managed Care

Patients With AD Prioritize Itch Control in Treatment Preferences

A US-based discrete choice experiment survey found that patients with atopic dermatitis (AD) prioritize treatments that effectively control itching. Because of the differences in health care and ...
The American Journal of Managed Care

The Patient Journey: Effectively Managing AD Itch Early On

The panel delves into the most challenging symptoms of atopic dermatitis (AD), maps out the patient journey, and highlights crucial factors in effectively managing itch and other AD-related symptoms.
MM&M

J&J scratches AD itch by acquiring experimental eczema antibody for $1.25B

Johnson & Johnson announced it will pay $1.25 billion to buy an experimental bispecific antibody targeting atopic dermatitis (AD) from Numab Therapeutics. The all-cash deal, which was announced ...
Business Wire

Incyte Announces Results from SCRATCH-AD Trial Demonstrating Substantial and Rapid Itch Reduction in Patients with Mild-Moderate Atopic Dermatitis Treated with Opzelura ...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced new data from the Phase 2 SCRATCH-AD trial evaluating the short-term clinical benefits of Opzelura ® (ruxolitinib) cream 1.5% to ...
Healio

VIDEO: How to understand the ‘ferocious cycle’ of itch in atopic dermatitis

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. Mostly, the underlying mechanisms that we ...